Introduction
Guidelines published by the Global Initiative for Asthma indicate that asthma control can and should be achieved and maintained in most patients by employing appropriate pharmacotherapy and minimising environmental stimuli (1, 2) . However, this goal is not always met and the majority of patients still remain uncontrolled. In a recent survey of over 2000 adults diagnosed with asthma in five European countries only 38% of treated patients were well controlled, and in Germany this figure was lower, at 26% (3). Currently, initial treatment generally consists of a fixed low dose of an inhaled corticosteroid (ICS) (200-500 lg beclomethasone dipropionate equivalent) with a short-acting b 2 -agonist (SABA) for
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Aims: This retrospective, observational cohort study aimed to compare treatment outcomes and healthcare costs in the year after initiation of maintenance treatment with budesonide ⁄ formoterol or salmeterol ⁄ fluticasone in a German healthcare setting. Methods: Data on German asthma patients initiating treatment with budesonide ⁄ formoterol or salmeterol ⁄ fluticasone between June 2001 and June 2005 were obtained from the IMS Disease Analyzer database. The primary outcome was the probability of treatment success, defined according to short-acting b 2 -agonist prescriptions and switches or addition of controller medications, during the postindex year. A secondary definition of treatment success included hospitalisations and oral corticosteroid (OCS) prescriptions. Secondary outcomes included severe asthma exacerbations, defined as ‡1 OCS prescription, asthma-related hospitalisation and ⁄ or referral. The effect of treatment on costs was estimated using generalised linear models, adjusting for patient and physician characteristics. Results: There were no significant differences between the budesonide ⁄ formoterol (n = 1456) and salmeterol ⁄ fluticasone (n = 982) groups in disease severity markers in the pre-index year. Patients on budesonide ⁄ formoterol had a 44% greater probability of treatment success [odds ratio (OR): 1.44; p = 0.0003] according to the primary definition and a 26% greater probability (OR: 1.26; p = 0.0119) according to the secondary definition, fewer severe exacerbations ()33.4%; p = 0.0123) and fewer OCS prescriptions ()31.5%; p = 0.0082) compared with salmeterol ⁄ fluticasone, after controlling for baseline characteristics. Adjusting for covariates, budesonide ⁄ formoterol had a significant inverse relationship on asthma-related costs compared with salmeterol ⁄ fluticasone ()13.4%; p < 0.001). Total cost (asthma-and non-asthma-related costs) was 12.6% lower for budesonide ⁄ formoterol (p < 0.0001). Conclusion: This study suggests that for patients with chronic asthma in Germany, budesonide ⁄ formoterol rather than salmeterol ⁄ fluticasone had a higher likelihood of treatment success, and that budesonide ⁄ formoterol is the less costly option. Although the cohorts appeared to be well matched at baseline, the results should be interpreted with caution given the observational nature of the study. symptom relief as needed (1, 2) . Clinical trials have demonstrated that, in patients in whom asthma is not controlled with low-dose ICS, the combination of an ICS and a long-acting b 2 -agonist (LABA) improves asthma control more effectively than higher doses of ICS alone (4) (5) (6) (7) . This combination is now the recommended maintenance therapy for patients stepping up from low-dose ICS (1,2). Fixed-dose combination inhalers have been developed, which offer improved convenience over ICS and LABA administered in separate devices and ensure better long-term compliance to anti-inflammatory therapy (8) . Two previous database studies indicated that combination products improve both compliance and treatment outcomes compared with the concurrent administration of individual products via separate inhalers (9,10). The two most commonly used fixed combination products,
AstraZeneca, Lund, Sweden) and salmeterol ⁄ fluticasone (SeretideÔ, GlaxoSmithKline, Uxbridge, UK or VianiÔ, GlaxoSmithKline), have both been shown to be highly effective in patients with persistent asthma that is uncontrolled with ICS alone (6, (11) (12) (13) (14) (15) . Randomised controlled studies in moderate-to-severe asthma have shown similar daily or weekly control and overall exacerbation rates for both combinations when used as fixed-dose maintenance therapy (16) (17) (18) . Nevertheless, in the study by Kuna and colleagues and a recent meta-analysis of three clinical trials, including over 4000 patients, it was found that the risk or rate of exacerbations requiring hospitalisations ⁄ emergency treatments was lower with sustained fixed-dose budesonide ⁄ formoterol than with sustained fixed-dose salmeterol ⁄ fluticasone (18) (19) (20) . This important efficacy difference was consistent in all three of the individual studies included in the analysis. Two recent meta-analyses also indicate that these two combinations may have different effects on asthma-related hospitalisations. In an analysis assessing the safety of formoterol administered in combination with an ICS in 18 double-blind clinical studies, fewer asthma-related hospitalisations and asthma-related serious adverse events were observed in the formoterol ⁄ ICS group compared with the ICS-alone control group (21) . These results were independent of the ICS dose in the control group. In contrast, an analysis of 52 clinical studies of salmeterol showed no difference in asthma-related hospitalisations when salmeterol was added to an ICS compared with ICS alone (22) . Thus, it appears that combination therapies may not have the same level of efficacy across all outcome measures important in asthma management. It is not certain if the reduced risk of requiring hospitalisation ⁄ emergency treatment with budesonide ⁄ formoterol compared with salmeterol ⁄ fluticasone in meta-analyses of randomised controlled trials is likely to be seen in the normal clinical setting. In this case, database studies can provide valuable information on how these commonly used combination therapies affect cost-driving outcomes, such as exacerbations, in everyday practice. Such analyses are also important for establishing the overall relative cost-effectiveness of initiating treatment with combinations of budesonide ⁄ formoterol or salmeterol ⁄ fluticasone in asthma patients. The relative effectiveness and cost-effectiveness of initiating maintenance therapy with budesonide ⁄ formoterol and salmeterol ⁄ fluticasone under standard clinical conditions in Germany is not known. The aim of this retrospective database cohort study was to compare treatment outcomes and healthcare costs in the year after the initiation of maintenance treatment with budesonide ⁄ formoterol or salmeterol ⁄ fluticasone in a German healthcare setting.
Methods

Sources of data
This study was a retrospective database cohort study carried out using data obtained from the IMS Disease Analyzer database (http://www.imshealth.com). This is a database that captures real-life, longitudinal, anonymised data on patients and prescribers across Europe. In Germany, approximately 2000 physicians record data on 10 million patients. The data recorded include patient demographics, physician characteristics, prescriptions, hospital admissions and specialist referrals.
Patient population
The cohorts identified for the study included patients who initiated maintenance treatment with budesonide ⁄ formoterol or salmeterol ⁄ fluticasone between June 2001 and June 2005. Budesonide ⁄ formoterol is reported to be effective when used as both maintenance and reliever therapy compared with traditional ICS ⁄ LABA combinations plus SABA (18, 23, 24) . However, during the time period when the data used in this study was recorded, budesonide ⁄ formoterol was approved for use as maintenance treatment only. In this study, the index date was defined as the date of their first prescription of ICS ⁄ LABA combination. Eligible patients were over 12 years of age, had a diagnosis of asthma (ICD-10 codes J45-46) and continuous enrolment in the database from 12 months prior to the index date to 12 months after the index date (IMS data was collected between June 2000 and June 2006). Patients with diagnosed chronic obstructive pulmonary disease or use of ICS ⁄ LABA prior to the launch of budesonide ⁄ formoterol in Germany (June 2001) were excluded.
Treatment outcomes
The predefined primary end-point was the probability of full treatment success vs. partial or no treatment success over 12 months following first prescription of an ICS ⁄ LABA combination therapy. Treatment success was defined a priori according to primary or secondary criteria as described in Table 1 . All events were assumed to be asthma related if a code for asthma diagnosis (ICD-10 codes J45-J46) was recorded on the same date. In case there was no link to diagnosis for an event, an algorithm was used to define whether an event was related to asthma. Hospitalisations, referrals and oral corticosteroid (OCS) prescriptions were assumed to be related to asthma if they occurred within the 7 days before or after an event with a recorded diagnosis of asthma. Referrals associated with asthma were defined as all referrals to either a pneumologist or an allergologist.
Secondary outcomes included asthma exacerbations, SABA use, overall OCS prescriptions and asthma-related referrals and hospitalisations ⁄ emergency room visits. Asthma exacerbations were defined as any event (prescription, hospitalisation, sick note or referral) with a diagnosis of acute severe asthma status (ICD-10 code J46) or any asthma-related OCS prescription occurring within the 7 days before or the 7 days after an event with recorded diagnosis of asthma or acute lower respiratory tract infection (ICS-10 codes J45, J46, J22), or any referral or hospitalisation occurring within 7 days before or after an event with recorded diagnosis of asthma or acute lower respiratory tract infections. In cases where two or more acute exacerbations occurred within 7 days, it was counted as only one episode. The proportion of patients that did not renew their initial prescription was investigated as a measure of discontinuations.
Cost analysis
The health economic evaluation was conducted from a third-party payer perspective and compared costs related to each therapy in terms of medications and other asthma-related healthcare resource use. Unit costs for asthma medications were estimated from producer sales prices using a program provided by IMS. For budesonide ⁄ formoterol and salmeterol ⁄ fluticasone, 2007 ⁄ 2008 prices were obtained from the Rote Liste (http://www.rote-liste.de). Costs for physician consultations and outpatient procedures were obtained from the Einheitbewertungsmaßstab schedules and costs for hospitalisations came from the German refined diagnosis-related groups (http:// www.g-drg.de/) ( Table 2) . 
Statistical analysis
Logistic regression was used to estimate the association between treatment group and treatment success, adjusting for patient characteristics. Treatment success was modelled as a dichotomic variable, grouping the categories 'partial success' and 'no success' together. Potential covariates included disease severity according to treatment history, age and insurance status, and centre characteristics according to the physician and the specialty of the lead physician.
Covariates that were not statistically significant at the 5% level were removed. Renewal rates of ICS ⁄ LABA prescriptions were assessed as a measure of treatment persistence. Generalised linear models were used to estimate the effect of treatment on severe exacerbations, resource use and costs, adjusting for patient and physician characteristics. The choice of statistical distribution was based on goodness-of-fit statistics, which lead to the application of lognormal and gamma distributions, depending on the type of resource or cost modelled.
Results
Patients
Among the 2438 patients who met the study inclusion criteria, 1456 were treated with budesonide ⁄ formoterol (administered via Turbuhaler) and 982 were treated with salmeterol ⁄ fluticasone (administered via Diskus in the majority of patients). These patients represented 7.1% and 4.8% of the database respectively ( Figure 1 ). The majority of exclusions were due to patients not fulfilling 24 months of follow-up or having no history of asthma. Patient characteristics are summarised in In both groups, the majority of patients were followed at a general practitioner (GP)-lead clinic and the minority were followed at a specialist-lead practice. However, comparison of the two groups showed a higher proportion of patients at GP-lead clinics in It was assumed that two spirographies and one body plethysmography were conducted for all referrals. àAn estimated average cost calculated from the three G-DRG associated with a possible main diagnosis of asthma or acute exacerbation. This weighted average cost was calculated based on the number of cases associated with one asthma diagnosis and a co-payment of €10 per hospital day was applied. §Unit costs obtained from G-DRG (http://www.g-drg.de/). G-DRG, German refined diagnosis-related groups; EBM, Einheitbewertungsmaßstab.
the budesonide ⁄ formoterol group and a higher proportion of patients followed by specialists in the salmeterol ⁄ fluticasone group. These differences resulted in a statistically significant association between treatment group and type of practice (p = 0.0022). Insurance status also differed significantly g g between treatment groups (p = 0.0008). More patients in the budesonide ⁄ formoterol group had a company health insurance fund, while more patients in the salmeterol ⁄ fluticasone group had private insurance.
Treatment success
A higher proportion of patients in the budesonide ⁄ formoterol cohort met the criteria for primary and secondary treatment success compared with the salmeterol ⁄ fluticasone cohort (unadjusted analysis; Figure 2 ). As expected, the proportion of successfully treated patients for both budesonide ⁄ formoterol and salmeterol ⁄ fluticasone was lower when applying the secondary definition, which included OCS use and referrals ( Figure 2 ). For both definitions of treatment success, a larger proportion of patients in the salmeterol ⁄ fluticasone group, compared with the budesonide ⁄ formoterol group, failed to meet each of the subcriteria for full success (37.5% vs. 31.7%, Table 4 ). The most common reasons for treatment failure in both groups were addition of another asthma medication, SABA use at > 0.5 doses ⁄ day (DPI equivalent) and two or more asthma-related referrals (Table 4 ).
In the logistic regression model adjusted for disease severity and pre-index SABA use, the odds for achieving the primary definition of 'full success' vs. 'partial or no success' increased by 44% with budesonide ⁄ formoterol [odds ratio (OR): 1.44; p = 0.0003, Figure 3 ]. Patients treated with budesonide ⁄ formoterol also had a greater probability of treatment Subgroup analyses were conducted according to prescription renewal of ICS ⁄ LABA combination treatment. The logistic regression model for the primary definition of treatment success showed a significant treatment effect with budesonide ⁄ formoterol for the subgroup of the 1169 patients who did not renew their initial prescription (OR: 1.422; p = 0.0333) and for the 1269 patients with at least two prescriptions (OR: 1.426; p = 0.0064). For the 586 patients with a prescription renewal within 4 months of index date the OR was 1.214, which did not reach statistical significance (p = 0.3011).
Other treatment outcomes
A significantly higher number of severe exacerbations was observed among patients treated with salmeterol ⁄ fluticasone compared with budesonide ⁄ formoterol in the unadjusted analysis (0.1955 vs. 0.103 episodes per patient per year; p = 0.0018; Table 5 ). Linear regression analysis (adjusted for pre-index ICS, LABA and SABA use, gender and numbers of exacerbations, OCS prescriptions, referrals and hospitalisations over the pre-index period) indicated that budesonide ⁄ formoterol reduced the number of severe exacerbations by 33.4% compared with salmeterol ⁄ fluticasone (p = 0.0123). There was no statistically significant 
Costs
Total mean asthma-related costs were significantly greater for the salmeterol ⁄ fluticasone group compared with the budesonide ⁄ formoterol group (Figure 4) . The biggest differences were seen for asthma-related medications and asthma-related visits, for which costs were significantly greater for the salmeterol ⁄ fluticasone group than the budesonide ⁄ formoterol group. Mean costs associated with asthma-related referrals and hospitalisations were not significantly different between treatment groups. A generalised linear model using a log-normal distribution was used to estimate the effect of treatment on costs. When adjusting for covariates, budesonide ⁄ formoterol reduced total asthma-related costs ()13.4%: p < 0.001) compared with salmeterol ⁄ fluticasone. Total cost, including both asthma-related (medication, visits, referrals and hospitalisations) and non-asthma-related (medications and visits) costs, was 17.1% lower for budesonide ⁄ formoterol compared with salmeterol ⁄ fluticasone in the crude comparison (683.57€ vs. 824.67€; p = 0.0001) and 12.6% lower in the adjusted analysis (p < 0.0001).
Discussion
Clinical studies have shown that for patients with asthma uncontrolled by low-dose ICS treatment, fixed-dose combinations of an ICS and a LABA are Figure 4 Crude comparison of costs in the postindex year between salmeterol ⁄ fluticasone-(white bars) and budesonide ⁄ formoterol-(black bars) treated patients. p-values were derived using an unequal variance t-test more effective than either ICS alone or separately administered ICS and LABA (8) (9) (10) . This database analysis of fixed-dose ICS ⁄ LABA combinations adds to a growing body of evidence suggesting that there may be efficacy differences between budesonide ⁄ formoterol and salmeterol ⁄ fluticasone across certain cost-driving outcomes. The results suggest that, in a German healthcare setting, better outcomes can be achieved at a lower overall cost if patients are treated with budesonide ⁄ formoterol instead of salmeterol ⁄ fluticasone.
The economic cost of asthma is considerable both in terms of direct medical costs (such as hospital admissions and cost of pharmaceuticals) and indirect costs (such as time lost from work and premature death). Ineffective management of asthma can increase these costs, and the overall cost-effectiveness of new therapies is an important consideration. Economic analyses in Sweden have shown that combining budesonide and formoterol in one device may be cost-effective compared with the two agents administered separately (25, 26) . This study is the first of its kind to compare the cost-effectiveness of budesonide ⁄ formoterol and salmeterol ⁄ fluticasone using a German database analysis. The analysis indicates that, relative to the use of salmeterol ⁄ fluticasone, budesonide ⁄ formoterol treatment is less costly and is associated with a greater rate of treatment success in the German healthcare setting. The difference in cost appeared to be driven by fewer physician visits and lower expenditure on medications in the treatment practices where budesonide ⁄ formoterol was commonly used than in the practices where salmeterol ⁄ fluticasone was used. In database surveys, both the clinician and the treatment are likely to influence outcomes. Of note, in this analysis there were some differences between the two treatment groups in terms of lead physician type and insurance status. A higher proportion of patients in the budesonide ⁄ formoterol group were followed at a GP-lead clinic, while a higher proportion of the salmeterol ⁄ fluticasone group were followed at a specialist-lead clinic. Although statistically significant, these differences were small and have been controlled for through the use of regression analyses.
The fact that a high proportion of patients did not continue treatment with ICS ⁄ LABA for the whole study period, particularly in the budesonide ⁄ formoterol group, commands caution in interpreting the results. However, the effect of budesonide ⁄ formoterol on treatment success in the subgroup of patients who did not renew their initial prescription (OR: 1.422; p = 0.0333) was similar to the effect estimated in the whole sample, using logistic regression. Among patients with at least one prescription renewal within 4 months of the index date, the probability of treatment success was also higher for those treated with budesonide ⁄ formoterol, although the corresponding effect was not statistically significant. The ICS ⁄ LABA prescription renewal rates observed in this analysis are similar to those reported in a pharmacy database study investigating salmeterol ⁄ fluticasone adherence and persistence in 5504 patients in the USA (27) . More than half the patients filled a 30-day prescription only once over a 1-year interval, suggesting that adherence to ICS ⁄ LABA combinations may be considerably lower than those reported in clinical trials. Evidence also indicates that, in 'real-life', adherence to asthma therapy is greater among patients using fixed-dose combination inhalers compared with those prescribed separate ICS and LABA inhalers (8) .
As with all database studies there are several other limitations not usually encountered in controlled clinical trials that must be considered. Lack of follow-up between practices and the absence of any record of medications prescribed by specialists could lead to underestimation of prescriptions. However, this is unlikely to account for the differences observed between treatment groups in this comparative study as pre-index referrals and asthma-related prescriptions were similar between the two groups. Missing diagnoses and the use of algorithms to identify asthma-related events may also affect the results; however, this is also unlikely to have resulted in any significant bias in this study because proportions of missing diagnoses between treatment groups were similar. Of note, the probability of success was significantly higher in the budesonide ⁄ formoterol group in analyses using other variants of the definition of treatment success, taking into account events not related to asthma (results not reported). Furthermore, costs were lower in the budesonide ⁄ formoterol group regardless of whether costs unrelated to asthma, including costs for other medications and non-asthma-related physician visits, were included or not.
Two key objectives listed in guidelines for the successful management of chronic asthma are to achieve and maintain control of symptoms and to reduce or prevent asthma exacerbations. The results of this study suggest that in the German healthcare setting these goals are achieved more often in patients prescribed budesonide ⁄ formoterol than in patients prescribed salmeterol ⁄ fluticasone, and that budesonide ⁄ formoterol appears to represent a more cost-effective option based on the available evidence. Although the cohorts appeared to be well matched at baseline, the results should be interpreted with caution given the observational nature of the study.
